With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...

A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments head-to-head—proton beam therapy and intensity-modulated radiation therapy, or ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...

For patients with intermediate- or low-risk localized prostate cancer, intensity-modulated radiation therapy (IMRT) and proton beam therapy are both safe and effective options, according to results of ...

WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways to mitigate side effects. Patients with prostate cancer who receive ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

Mack Roach, III, MD, FASTRO, has been chosen by the American Society for Radiation Oncology (ASTRO) to receive its 2024 Gold Medal Award. Roach is being recognized with ASTRO’s highest honor for his ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...